System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 42851493 DOI: 10.3389/fphar.2026.1819323

Toxicoproteomics of APAP-exposed HepG2 cells identifies candidate translational biomarkers of liver injury and recovery.

Front Pharmacol 17:1819323

Authors: Ana S Serras, Sérgio P Camões, Rui Vitorino, Joana P Miranda

Affiliations

  • Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
  • LAQV/REQUIMTE, Mass Spectrometry Center, Department of Chemistry, University of Aveiro, Aveiro, Portugal.
  • Department of Surgery and Physiology, Cardiovascular R&D Center, Faculty of Medicine, University of Porto, Oporto, Portugal.
  • Department of Medical Sciences, Institute of Biomedicine iBiMED, University of Aveiro, Aveiro, Portugal.

Abstract

INTRODUCTION

Drug-induced liver injury (DILI) is a leading cause of acute liver failure (ALF) and a major obstacle in drug development, reflecting the lack of robust, mechanism-based biomarkers. Human in vitro systems, coupled with unbiased omics, provide controlled, human-relevant and mechanistically informative platforms that can accelerate biomarker discovery. Here, we explore quantitative toxicoproteomics of paracetamol (acetaminophen; APAP)-exposed HepG2 cells as a platform for the identification of candidate translational biomarkers of APAP-liver injury and recovery.

METHODS

HepG2 cells were exposed to the APAP IC 50 concentration for 8 h (injury phase), followed by drug withdrawal and a 24 h recovery phase. Injury-induced cell responses were evaluated through RT-qPCR analysis and intracellular ROS quantification. Proteomic changes associated with injury and recovery were characterized by quantitative LC-MS/MS and selected proteins were validated by immunoblotting.

RESULTS

LC-MS/MS quantified 1,478 proteins and revealed increased protein secretion upon APAP exposure. Notably, comparison of the proteomic dataset against published proteomic profiles of a large cohort of ALF patients supported the potential clinical relevance of the obtained signature. Injury-phase upregulated proteins, including KRT18 and HMGB1, recapitulated known clinical DILI biomarkers. Similarly, recovery-phase was marked by clinical markers of liver regeneration, e.g., AFP, APOA1 and HP, enabling discrimination between injury and regeneration. HPD, S100A6 and TXNRD1 emerged as candidate diagnostic biomarkers, whilst SERPINA1 and complement components (C3, C5) showed prognostic potential.

CONCLUSION

Collectively, this study demonstrated how toxicoproteomics applied to human in vitro hepatic models, validated against clinical evidence, provide a relevant platform for the discovery of novel translational biomarkers of liver injury and recovery.

MeSH

Cells, Pharmaceutical Preparations, Hep G2 Cells, Recycling, Liver, Biomarkers, Acetaminophen